imlifidase
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Hansa Biopharma's portfolio. Molecular target: Antibodies.
- Target
- Antibodies
- Mechanism
- Antibodies hydrolytic enzyme
biotech
Hansa Biopharma
Hansa Biopharma AB
Hansa Biopharma drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Lund, SE HQ
2007 Founded
136 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Lund, SE
- Founded
- 2007
- Employees
- 136
- Programs
- 1
- Drugs
- 4
- Patents
- 0
Hansa Biopharma pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Hansa Biopharma drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Hansa Biopharma in public FDA and regional records.
-
Development asset linked to Hansa Biopharma in public FDA and regional records.
-
Development asset linked to Hansa Biopharma in public FDA and regional records.